Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AZD1390
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Global Coalition for Adaptive Research Announces Initiation of AZD1390 in GBM AGILE Trial
Details : AZD1390 is a brain penetrant ataxia telangiectasia mutant (ATM) kinase inhibitor that blocks ATM-dependent signaling and repair of DNA double strand breaks (DSBs) in the genome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : AZD1390
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SLS-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : SLS-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Polaris Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-PEG 20 (pegargiminase) is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed, which is investigated for glioblastoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Pegargiminase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Polaris Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : Daridorexant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vilazodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : Vilazodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regorafenib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Regorafenib (stivarga) is an oral multikinase inhibitor that potently blocks multiple protein kinases, including kinases involved in oncogenesis, tumor angiogenesis, and tumor immunity.
Product Name : Stivarga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Regorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2022
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paxalisib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Kazia Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Kazia Provides Progress Update on GBM Agile Pivotal Study
Details : GDC-0084 (paxalisib), a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : Paxalisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Kazia Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apremilast,Eritoran,Hydrocortisone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amgen & Eisai to participate in the immune modulation domain of REMAP-COVID, an adaptive clinical trial to test interventions for patients hospitalized with COVID-19. Amgen’s Apremilast & Eisai’s Eritoran to be evaluated across multiple international...
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Apremilast,Eritoran,Hydrocortisone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable